In an unprecedented initiative, the two largest reproductive medical societies, namely, the European Society of Human Reproduction and Embryology (ESHRE) and the American Society of Reproductive Medicine (ASRM) joined forces with a leading-edge pharmaceutical company, Merck-Serono International, to create FertiQoL – the first internationally validated instrument to measure quality of life in individuals experiencing fertility problems.
FertiQoL is a measure of quality of life in people experiencing fertility problems. FertiQoL assesses the influences of fertility problems in diverse life areas, for example, on self-esteem, emotions, general health, partnership, family and social relationships, work life and future life plans. Additionally the optional FertiQoL Treatment module assesses the burden/tolerability of fertility treatment. It is hoped that FertiQoL will become the gold standard in measuring quality of life in people with fertility problems. FertiQoL was developed to improve clinical care and foster cross-country collaborations.
To this end clinicians and researchers are invited to use FertiQoL in upcoming projects, whether these be epidemiological surveys, cross-cultural studies, clinical trials or intervention projects aimed at identifying and addressing risk factors for poor adjustment to infertility or its treatment.